DelMar Pharma receives IND allowance from FDA to initiate clinical trials of VAL-083
DelMar Pharmaceuticals announced the FDA has allowed an additional IND to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer. VAL-083 is a first-in-class, DNA targeting agent that demonstrated clinical activity against a range of tumor-types in prior clinical trials. September 18, 2017